Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | Phase 2 | terminated | Oct 12, 2015 | Henrik Gregersen | Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide… | Other (stated, no rule matched) |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple… | Phase 1 | terminated | Nov 15, 2013 | M.D. Anderson Cancer Center | Terminated Phase I due to slow accrual without progression to Phase II. | Enrollment / accrual |
| NCT01121757 | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone… | Phase 2 | terminated | May 12, 2010 | Duke University | The study closed temporarily in February 2012 pending analysis of samples collected. In October,… | Other (stated, no rule matched) |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in… | Phase 2 / Phase 3 | terminated | Sep 25, 2009 | Shanghai Jiao Tong University School of Medicine | Very slow recruitment | Enrollment / accrual |
| NCT02230917 | A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple… | Phase 2 | withdrawn | Sep 3, 2014 | Rebecca Silbermann | not stated | Not stated |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT02640833 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic… | Phase 1 | withdrawn | Dec 29, 2015 | AbbVie | Study Stopped | Other (stated, no rule matched) |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | Phase 1 | terminated | Mar 2, 2010 | Steven P. Treon, MD, PhD | Safety concerns (IgM Flare) | Safety / toxicity |
| NCT01096810 | Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma | Phase 2 | terminated | Mar 31, 2010 | Jagannath, Sundar, M.D. | The research is permanently closed to enrollment. | Enrollment / accrual |
| NCT02739594 | Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma(COMPARE) | Phase 3 | terminated | Apr 15, 2016 | Hoffmann-La Roche | Slow recruitment | Enrollment / accrual |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Jan 28, 2014 | Ångstrom Pharmaceuticals | Slow enrollment | Enrollment / accrual |
| NCT02447055 | Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma | Early Phase 1 | withdrawn | May 18, 2015 | Washington University School of Medicine | not stated | Not stated |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | Phase 2 | terminated | Sep 24, 2009 | University of Utah | Lab Staff that was required left the institution, therefore accrual closed prematurely | Enrollment / accrual |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom… | Phase 2 | terminated | Feb 20, 2012 | Roswell Park Cancer Institute | funding was withdrawn | Funding |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | Phase 1 / Phase 2 | terminated | Aug 7, 2012 | National Cancer Institute (NCI) | study closed prematurely because investigator left National Institutes of Health | Investigator |
| NCT01182233 | Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic… | Phase 1 | terminated | Aug 16, 2010 | University of Rochester | low enrollment | Enrollment / accrual |
| NCT01807286 | Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis | Phase 1 | terminated | Mar 8, 2013 | M.D. Anderson Cancer Center | Sponsor requested termination | Other (stated, no rule matched) |
| NCT02735876 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus… | Phase 3 | withdrawn | Apr 13, 2016 | Acerta Pharma BV | not stated | Not stated |
| NCT00892346 | Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line… | Phase 3 | suspended | May 4, 2009 | Shanghai Jiao Tong University School of Medicine | No avaliability of melphlan in mainland China | Other (stated, no rule matched) |
| NCT01501370 | Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in…(ZLd_Ld) | Phase 2 | withdrawn | Dec 29, 2011 | Tiziana Marangon | not stated | Not stated |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | Phase 1 / Phase 2 | terminated | Dec 21, 2007 | Baylor College of Medicine | slow accrual | Enrollment / accrual |
| NCT01016028 | Chemotherapy-Induced Peripheral Neuropathy Survey | — | withdrawn | Nov 18, 2009 | M.D. Anderson Cancer Center | Study assessment tool development delayed. | Other (stated, no rule matched) |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Sep 2, 2005 | Dana-Farber Cancer Institute | Toxicity | Safety / toxicity |
| NCT01578343 | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma(ZOLINZA) | Phase 2 | terminated | Apr 16, 2012 | Samsung Medical Center | we collected data of a total of 19 patients for an interim analysis. but there are less than 7… | Efficacy / futility |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of… | Phase 1 / Phase 2 | terminated | Dec 2, 2009 | Cephalon | not stated | Not stated |
| NCT02140840 | UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the… | Phase 2 | withdrawn | May 16, 2014 | University of Arkansas | PI left institution | Investigator |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity… | Phase 2 | terminated | Feb 14, 2008 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | Phase 2 | terminated | Jan 25, 2012 | M.D. Anderson Cancer Center | Objectives not met. | Other (stated, no rule matched) |
| NCT00836173 | Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate,… | Phase 2 | withdrawn | Feb 4, 2009 | Loyola University | Gallium is no longer available for the conduct of this study. | Other (stated, no rule matched) |
| NCT02054559 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL(ASPIRE) | Phase 3 | withdrawn | Feb 4, 2014 | Asan Medical Center | No consensus among trial centers regarding protocol | Other (stated, no rule matched) |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | Phase 2 | terminated | Jun 15, 2006 | Asan Medical Center | poor accrual and response less than expected on interim analysis | Efficacy / futility |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma…(VEIL) | Phase 2 | terminated | Dec 28, 2011 | Peter MacCallum Cancer Centre, Australia | Poor recruitment rate | Enrollment / accrual |
| NCT01329289 | SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | Phase 2 | withdrawn | Apr 5, 2011 | University of Pittsburgh | Clinical trial being transferred to Columbia University with the Investigator. | Investigator |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects… | Phase 2 | terminated | Feb 24, 2009 | Januario Castro, M.D. | drug supply became unavailable | Drug supply |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | Phase 2 | terminated | Jul 20, 2009 | Januario Castro, M.D. | drug supply was no longer available | Drug supply |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Dec 18, 2007 | Dana-Farber Cancer Institute | Slow accrual led to early study termination. | Enrollment / accrual |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 10, 2009 | Georgetown University | Unable to accrue patients due to change in standard CLL therapy | Enrollment / accrual |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent… | Phase 1 | terminated | Oct 2, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | Phase 1 / Phase 2 | terminated | Jun 21, 2012 | Singapore General Hospital | Funding expired | Funding |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell… | Phase 1 | terminated | Jan 11, 2010 | Case Comprehensive Cancer Center | Extreme toxicity in Phase I, study did not proceed to Phase II | Safety / toxicity |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell… | Phase 1 | terminated | Feb 26, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic… | Phase 1 | terminated | May 19, 2010 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new… | Drug supply |
| NCT00578045 | UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies | Phase 1 | withdrawn | Dec 20, 2007 | University of Arkansas | no accrual | Enrollment / accrual |
| NCT02258555 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With… | Phase 1 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell… | Phase 2 | withdrawn | Dec 20, 2010 | UNC Lineberger Comprehensive Cancer Center | No patients enrolled and funding has been withdrawn. | Enrollment / accrual |
| NCT01180569 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Aug 12, 2010 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 20, 2016source: clinicaltrials